Clinical Trials Logo

ß-thalassemia clinical trials

View clinical trials related to ß-thalassemia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04054921 Completed - ß-thalassemia Clinical Trials

Safety Study for Beta Thalassemia Subjects on PTG-300

TRANSCEND
Start date: May 10, 2019
Phase: Phase 2
Study type: Interventional

In this study will investigate long term safety and use of the PTG-300 in Beta Thalassemia patients.

NCT ID: NCT03802201 Completed - ß-thalassemia Clinical Trials

Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia

TRANSCEND
Start date: December 19, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase 2 open-label, single-arm design study with dose escalation by subject cohort . The study is designed to monitor the PTG-300 safety profile, to obtain preliminary evidence of efficacy of PTG-300 for the treatment in β-thalassemia.

NCT ID: NCT03591900 Completed - Diabetes Clinical Trials

The Use of CGMS to Detect Alterations of Blood Glucose in Thalassemic Patients

Start date: April 2014
Phase: N/A
Study type: Interventional

The aim of the study is to: - Assess the pattern of glucose homeostasis in patients with B thalassemia . - To detect early impairment in glucose metabolism and prediabetic state in B thalassemia patients using continuous glucose monitoring system. - To study the prevalence and type of DM in B thalassemia patients. - A comparative study of standard insulin therapy compared to insulin pump therapy in thalassemic diabetic patients will be done. The study will include screening of 200 children and adolescents who are regularly attending the Hematology Oncology Clinic and fulfilling the inclusion criteria for abnormalities of glucose homeostasis. A pilot study will be done on 15 patients with abnormal glucose tolerance which will include: A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration . B-Therapeutic intervention: Thalassemia patients who proved to have diabetes according to the ADA criteria will be subjected to • Insulin pump will be tried in each diabetic thalassemic patient versus conventional insulin therapy.

NCT ID: NCT01863173 Completed - B Thalassemia Clinical Trials

Effect of Metoprolol on Thalassemia Cardiomyopathy

Start date: January 2012
Phase: Phase 2/Phase 3
Study type: Interventional

effect of B blocker was first evaluated in patient with cardiomyopathy not induced by ischemia and idiopathic which as the most common causes of cardiomyopathy. Effect of BB on Thalassemia cardiomyopathy was evaluated in this study

NCT ID: NCT01749540 Completed - B-Thalassemia Clinical Trials

Study to Evaluate the Effects of ACE-536 in Patients With Beta-thalassemia

Start date: February 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effects of ACE-536 in patients with beta-thalassemia.

NCT ID: NCT00560820 Completed - Clinical trials for Transfusional Iron Overload

Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload

Start date: September 2007
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the effect of deferasirox on renal hemodynamics by determining glomerular filtration rate (GFR), renal plasma flow (RPF) and filtration fraction (FF).